From Dystrophin to Function: A Patient-Centered Approach to Drug Development in Becker Muscular Dystrophy

• Moving beyond protein restoration towards meaningful functional improvement for patients
• Understanding why muscle function is what matters most to patients
• Exploring the clinical development of Sevasemten to reveal the lessons learned for future development of other muscular dystrophies
• Establishing the role of small molecules within an increasingly diversified treatment landscape

Speakers:

Nitza Thomasson

Executive Director, Global Head of Research & Development

Servier